ANDA 210738, held by Stevens J. Vardenafil Hydrochloride.
As of Nov 16, 2026, ANDA 210738 (Vardenafil Hydrochloride), held by Stevens J, was first approved by FDA on Oct 31, 2018, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 31, 2018 | Original application | Approved | None posted |
| Vardenafil HydrochlorideEQ 5MG BASE · tablet;oral | Vardenafil Hydrochloride | Discontinued |
| Vardenafil HydrochlorideEQ 10MG BASE · tablet;oral | Vardenafil Hydrochloride | Discontinued |
| Vardenafil HydrochlorideEQ 20MG BASE · tablet;oral | Vardenafil Hydrochloride | Discontinued |
| Feb 5, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 31, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters